1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Neuraxpharm CEO Confirms Expansion Into New Markets, Including US

Company’s Value-Added Segment Expected To Soon Account For Half Of Sales

 
• By Akriti Seth

In an exclusive interview with Generics Bulletin, Neuraxpharm CEO Jörg-Thomas Dierks reveals that the company plans to expand out of Europe into other markets by acquiring companies in regions such as the US.

Neuraxpharm CEO
Neuraxpharm’s Dierks talks about international expansion and becoming a European leader in Medical Cannabis • Source: Neuraxpharm

“Our main market is Europe, but we want to also go and look into other geographies of the world,” Neuraxpharm CEO Jörg-Thomas Dierks has told Generics Bulletin in an exclusive interview, as the company insisted that it was confident of its “very rich pipeline, developed not only for the European market but, in theory, for the global market.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.